Dr. Rodger Novak, Nabriva’s COO, will present an oral summary of the Company’s posters on pleuromutilin BC-3781 at the Session on “Novel antimicrobial agents” on Sunday, September 12th at 1:45 pm. He will be presenting data demonstrating BC-3781’s anti-microbial spectrum and it’s efficacy in non-clinical studies of both skin (ABSSSI) and lung infections, including community-acquired bacterial pneumonia (CABP), as well as data showing the pharmacokinetics of the molecule in clinical Phase I studies when administered intravenously.
Additionally, Nabriva’s CMO, Dr. William Prince will be presenting the latest research results on “Safety, Tolerance and Pharmacokinetics of Single and Repeat Doses of Oral BC-3781, a Novel Antimicrobial”. Study results showed that oral BC-3781 was well tolerated in patients and plasma concentration levels of BC-3781 indicated a therapeutic potential for the treatment of bacterial lung and skin infections. The presentation number is F1-1970 and it will be given on Wednesday, September 15th at 8:30- 8:45 am.
These studies will be presented at the 50th ICAAC in Boston, held on September 12- 15th 2010. The titles and contributors to each poster mentioned above are as follows:
Population Pharmacokinetics of BC-3781 Using Phase 1 Data C. M. Rubino, A. Forrest, S. M. Bhavnani, W. T. Prince, Z. Ivezic-Schoenfeld, W. W. Wicha, P. G. Ambrose
An Age and Gender Study Investigating the Safety, Tolerance and Pharmacokinetics of BC-3781 W. W. Wicha, C. Lell, D. K. Logan, W. T. Prince
Determination of Disk Diffusion and MIC Quality Control Ranges for BC-3781 using CLSI Multi-Laboratory M23-A3 Study Design J. E. Ross, R. N. Jones, H. S. Sader, Z. Ivezic-Schoenfeld
Activity BC-3781, a Novel Pleuromutilin Compound, Tested Against Clinical Isolates of MRSA, Including Molecularly Characterized Community-Acquired and Hospital-Associated Strains H. S. Sader, D. J. Biedenbach, Z. Ivezic Schoenfeld, S. Paukner, R. Novak, R. N. Jones
Antimicrobial Activity of The Investigational Pleuromutilin BC-3781 Against Organisms Responsible for Community-acquired Respiratory Tract Infections (CA-RTI) H. S. Sader, S. Paukner, Z. Ivezic Schoenfeld, F. J. Schmitz, D. J. Biedenbach, R. N. Jones
Efficacy of BC-3781 in Murine Pneumonia Models W. W. Wicha, Z. Ivezic Schoenfeld, R. Novak
In Vivo Pharmacodynamic Activity of BC-3781 W. A. Craig, D. Andes, Z. Ivezic Schoenfeld, R. Novak, W. W. Wicha
Pre-clinical Efficacy of BC-3781 in Thigh and Bacteremia Infections Caused by Staphylococci W. W. Wicha, Z. Ivezic Schoenfeld, R. Novak
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by S. aureus, , S. pneumoniae, H. influenza, Mycoplasma, Legionella and other bacteria, including drug resistant strains such as MRSA and vancomycin resistant E. faecium. In addition, Nabriva Therapeutics’ topical pleuromutilin product candidate, BC-7013, is in clinical phase I. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva Therapeutics is located in Vienna, Austria.
For more information on Nabriva please visit www.nabriva.com.
Contact: Nabriva Therapeutics AG College Hill Life Sciences Dr David Chiswell CEO T +43 (0)1 740 93-0 OFFICE@NABRIVA.COM Dr Douglas Pretsell Senior Account Director T +49 (0)89 57001806 douglas.pretsell@collegehill.com
